B-condition	0	4	Bone
I-condition	4	5	-
I-condition	5	12	related
I-condition	13	26	complications
I-condition	27	30	and
I-condition	31	38	quality
I-condition	39	41	of
I-condition	42	46	life
O	47	49	in
O	50	58	advanced
O	59	65	breast
O	66	72	cancer
O	72	73	:
O	74	81	results
O	82	86	from
O	87	88	a
O	89	99	randomized
O	100	105	phase
O	106	109	III
O	110	115	trial
O	116	118	of
B-intervention	119	128	denosumab
O	129	135	versus
B-control	136	146	zoledronic
I-control	147	151	acid
O	151	152	.

O	153	162	Denosumab
O	163	166	was
O	167	172	shown
O	173	175	to
O	176	178	be
O	179	187	superior
O	188	190	to
O	191	201	zoledronic
O	202	206	acid
O	207	209	in
O	210	220	preventing
O	221	229	skeletal
O	230	237	related
O	238	244	events
O	245	246	(
O	246	249	SRE
O	249	250	)
O	251	253	in
O	254	262	patients
O	263	267	with
O	268	274	breast
O	275	281	cancer
O	282	285	and
O	286	290	bone
O	291	301	metastases
O	302	304	in
O	305	306	a
O	307	317	randomized
O	317	318	,
O	319	325	double
O	325	326	-
O	326	331	blind
O	332	337	phase
O	338	341	III
O	342	347	study
O	347	348	.

O	349	351	We
O	352	361	evaluated
O	362	369	further
O	370	377	results
O	378	382	from
O	383	387	this
O	388	393	study
O	394	401	related
O	402	404	to
O	405	413	skeletal
O	414	427	complications
O	428	431	and
O	432	438	health
O	438	439	-
O	439	446	related
O	447	454	quality
O	455	457	of
O	458	462	life
O	463	464	(
O	464	469	HRQoL
O	469	470	)
O	470	471	.

O	472	480	Patients
O	481	485	were
O	486	496	randomized
O	497	498	1
O	498	499	:
O	499	500	1
O	501	503	to
O	504	511	receive
O	512	524	subcutaneous
O	525	534	denosumab
O	535	538	120
O	539	541	mg
O	542	543	(
O	543	544	n
O	545	546	=
B-intervention-participants	547	548	1
I-intervention-participants	548	549	,
I-intervention-participants	549	552	026
O	552	553	)
O	554	557	and
O	558	569	intravenous
O	570	577	placebo
O	577	578	,
O	579	581	or
O	582	593	intravenous
O	594	604	zoledronic
O	605	609	acid
O	610	611	4
O	612	614	mg
O	615	616	(
O	616	617	n
O	618	619	=
B-control-participants	620	621	1
I-control-participants	621	622	,
I-control-participants	622	625	020
O	625	626	)
O	627	630	and
O	631	643	subcutaneous
O	644	651	placebo
O	652	657	every
O	658	659	4
O	660	665	weeks
O	665	666	.

O	667	675	Analyses
O	676	684	reported
O	685	689	here
O	690	697	include
O	698	701	the
O	702	712	proportion
O	713	715	of
O	716	724	patients
O	725	729	with
O	730	733	one
O	734	736	or
O	737	745	multiple
O	746	748	on
O	748	749	-
O	749	754	study
O	755	759	SREs
O	759	760	,
O	761	765	time
O	766	768	to
O	769	774	first
O	775	784	radiation
O	785	787	to
O	788	792	bone
O	792	793	,
O	794	798	time
O	799	801	to
O	802	807	first
O	808	811	SRE
O	812	814	or
O	815	828	hypercalcemia
O	829	831	of
O	832	842	malignancy
O	842	843	,
O	844	847	and
O	848	854	change
O	855	857	in
O	858	863	HRQoL
O	864	865	(
O	865	875	functional
O	876	886	assessment
O	887	889	of
O	890	896	cancer
O	897	904	therapy
O	904	905	-
O	905	912	general
O	912	913	)
O	913	914	.

O	915	920	Fewer
O	921	929	patients
O	930	939	receiving
O	940	949	denosumab
O	950	954	than
O	955	965	zoledronic
O	966	970	acid
O	971	974	had
O	975	977	an
O	978	980	on
O	980	981	-
O	981	986	study
B-outcome	987	990	SRE
O	991	992	(
B-iv-bin-percent	992	994	31
I-iv-bin-percent	994	995	%
O	996	998	vs
O	998	999	.
B-cv-bin-percent	1000	1002	36
I-cv-bin-percent	1002	1003	%
O	1003	1004	,
O	1005	1006	P
O	1007	1008	=
O	1009	1010	0
O	1010	1011	.
O	1011	1014	006
O	1014	1015	)
O	1015	1016	.

O	1017	1020	The
B-outcome	1021	1030	incidence
I-outcome	1031	1033	of
I-outcome	1034	1039	first
I-outcome	1040	1049	radiation
I-outcome	1050	1052	to
I-outcome	1053	1057	bone
O	1058	1061	was
B-iv-bin-percent	1062	1064	12
I-iv-bin-percent	1064	1065	%
O	1066	1067	(
O	1067	1068	n
O	1069	1070	=
B-iv-bin-abs	1071	1074	123
O	1074	1075	)
O	1076	1080	with
O	1081	1090	denosumab
O	1091	1097	versus
B-cv-bin-percent	1098	1100	16
I-cv-bin-percent	1100	1101	%
O	1102	1103	(
O	1103	1104	n
O	1105	1106	=
B-cv-bin-abs	1107	1110	162
O	1110	1111	)
O	1112	1116	with
O	1117	1127	zoledronic
O	1128	1132	acid
O	1132	1133	.

O	1134	1143	Denosumab
O	1144	1153	prolonged
O	1154	1157	the
B-outcome	1158	1162	time
I-outcome	1163	1165	to
I-outcome	1166	1171	first
I-outcome	1172	1181	radiation
I-outcome	1182	1184	to
I-outcome	1185	1189	bone
O	1190	1192	by
O	1193	1195	26
O	1195	1196	%
O	1197	1203	versus
O	1204	1214	zoledronic
O	1215	1219	acid
O	1220	1221	(
O	1221	1223	HR
O	1223	1224	,
O	1225	1226	0
O	1226	1227	.
O	1227	1229	74
O	1229	1230	;
O	1231	1233	95
O	1233	1234	%
O	1235	1245	confidence
O	1246	1254	interval
O	1255	1256	[
O	1256	1258	CI
O	1258	1259	]
O	1259	1260	,
O	1261	1262	0
O	1262	1263	.
O	1263	1265	59
O	1265	1266	-
O	1266	1267	0
O	1267	1268	.
O	1268	1270	94
O	1270	1271	,
O	1272	1273	P
O	1274	1275	=
O	1276	1277	0
O	1277	1278	.
O	1278	1281	012
O	1281	1282	)
O	1283	1286	and
O	1287	1296	prolonged
O	1297	1300	the
B-outcome	1301	1305	time
I-outcome	1306	1308	to
I-outcome	1309	1314	first
I-outcome	1315	1318	SRE
I-outcome	1319	1321	or
I-outcome	1322	1335	hypercalcemia
I-outcome	1336	1338	of
I-outcome	1339	1349	malignancy
O	1350	1352	by
O	1353	1355	18
O	1355	1356	%
O	1357	1358	(
O	1358	1360	HR
O	1360	1361	,
O	1362	1363	0
O	1363	1364	.
O	1364	1366	82
O	1366	1367	;
O	1368	1370	95
O	1370	1371	%
O	1372	1374	CI
O	1374	1375	,
O	1376	1377	0
O	1377	1378	.
O	1378	1380	70
O	1380	1381	-
O	1381	1382	0
O	1382	1383	.
O	1383	1385	95
O	1385	1386	;
O	1387	1388	P
O	1389	1390	=
O	1391	1392	0
O	1392	1393	.
O	1393	1396	007
O	1396	1397	)
O	1397	1398	.

B-iv-bin-percent	1399	1402	Ten
I-iv-bin-percent	1403	1410	percent
O	1411	1415	more
O	1416	1424	patients
O	1425	1428	had
O	1429	1430	a
O	1431	1441	clinically
O	1442	1452	meaningful
B-outcome	1453	1464	improvement
I-outcome	1465	1467	in
I-outcome	1468	1473	HRQoL
O	1474	1478	with
O	1479	1488	denosumab
O	1489	1497	relative
O	1498	1500	to
O	1501	1511	zoledronic
O	1512	1516	acid
O	1516	1517	,
O	1518	1528	regardless
O	1529	1531	of
O	1532	1540	baseline
O	1541	1545	pain
O	1546	1552	levels
O	1552	1553	.

O	1554	1563	Denosumab
O	1564	1567	was
O	1568	1576	superior
O	1577	1579	to
O	1580	1590	zoledronic
O	1591	1595	acid
O	1596	1598	in
O	1599	1607	reducing
O	1608	1612	bone
O	1612	1613	-
O	1613	1620	related
O	1621	1634	complications
O	1635	1637	of
O	1638	1648	metastatic
O	1649	1655	breast
O	1656	1662	cancer
O	1663	1666	and
O	1667	1677	maintained
O	1678	1683	HRQoL
O	1683	1684	,
O	1685	1694	providing
O	1695	1697	an
O	1698	1709	efficacious
O	1709	1710	,
O	1711	1715	well
O	1715	1716	-
O	1716	1725	tolerated
O	1726	1735	treatment
O	1736	1742	option
O	1743	1746	for
O	1747	1755	patients
O	1756	1760	with
O	1761	1765	bone
O	1766	1776	metastases
O	1777	1781	from
O	1782	1788	breast
O	1789	1795	cancer
O	1795	1796	.
